Belite Bio, Inc
BLTE
Rang in aandelen
#3054
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Aandeelprijs
$148.24
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$5.97B
Verandering (1 dag)
3.82%
Verandering (1 jaar)
64.04%
Land
US
Handel Belite Bio, Inc (BLTE)
Categorie
Healthcare
Winst voor Belite Bio, Inc (BLTE)
Winst in Jun 2026 TTM: $-102.31M
Volgens de meest recente financiële verslagen van Belite Bio, Inc bedraagt de huidige winst van het bedrijf $-102.31M. In 2023 behaalde het bedrijf een winst van $-31.62M, een daling ten opzichte van de winst van 2022, die $-12.65M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Belite Bio, Inc van 2020 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-102.31M | 183.11% |
| 2024 | $-36.14M | 14.28% |
| 2023 | $-31.62M | 150.02% |
| 2022 | $-12.65M | 30.85% |
| 2021 | $-9.67M | 68.05% |
| 2020 | $-5.75M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -5,255.85% |
US
|
|
| $-3.09B | 2,917.33% |
US
|
|
| $-4.02B | 3,825.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,006.63% |
NL
|
